Last reviewed · How we verify
De-escalated Dual Antiplatelet Therapy
De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.
De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection. Used for Acute coronary syndrome with percutaneous coronary intervention, Stable coronary artery disease with stent placement in high bleeding risk patients.
At a glance
| Generic name | De-escalated Dual Antiplatelet Therapy |
|---|---|
| Also known as | De-escalation |
| Sponsor | China National Center for Cardiovascular Diseases |
| Drug class | Antiplatelet therapy regimen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This therapeutic strategy involves shortening the period of dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) or using lower doses compared to standard regimens. The approach aims to balance the prevention of stent thrombosis and recurrent ischemic events against the increased bleeding complications associated with prolonged dual therapy, particularly in patients at high bleeding risk.
Approved indications
- Acute coronary syndrome with percutaneous coronary intervention
- Stable coronary artery disease with stent placement in high bleeding risk patients
Common side effects
- Stent thrombosis
- Recurrent myocardial infarction
- Bleeding complications
Key clinical trials
- Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: